Core Insights - Pulse Biosciences, Inc. has announced late-breaking clinical data from its nPulse Cardiac Catheter first-in-human feasibility study, showcasing the successful treatment of atrial fibrillation in 150 patients [1] - The study highlights rapid procedure times and minimal adverse effects associated with the use of the proprietary Nanosecond Pulsed Field Ablation technology [1] Company Overview - Pulse Biosciences, Inc. is focused on developing innovative medical technologies, specifically utilizing nanosecond PFA energy for cardiac treatments [1] - The company is publicly traded on Nasdaq under the ticker symbol PLSE [1] Clinical Study Details - The feasibility study involved 150 patients and demonstrated effective treatment outcomes for atrial fibrillation [1] - The results were presented at the 31st Annual event, indicating the significance of the findings in the medical community [1]

Group 1 - Pulse Biosciences, Inc. is set to present at the 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco on January 14, 2026, at 3:45 PM PT [1][2] - The company utilizes its proprietary nPulse™ technology, which employs Nanosecond Pulsed Field Ablation (nsPFA) to deliver nanosecond pulses of electrical energy for non-thermal cell clearance while preserving adjacent noncellular tissue [3] - Pulse Biosciences aims to develop its nPulse technology for treating atrial fibrillation and other markets, potentially enhancing healthcare outcomes for patients and providers, particularly in surgical soft tissue ablation [3]